In the Press COUR Pharmaceuticals Announces Late-Breaking Poster for Phase 2a Data of CNP-104 in Primary Biliary Cholangitis Accepted for Presentation at The Liver Meeting® 2024 October 2024 Read More COUR Pharmaceuticals Announces Positive Top-line Results from Phase 2a Study of CNP-104 in Primary Biliary Cholangitis September 2024 Read More COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives August 2024 Read More COUR Pharmaceuticals Appoints Tim Walbert to its Board of Directors June 2024 Read More
COUR Pharmaceuticals Announces Late-Breaking Poster for Phase 2a Data of CNP-104 in Primary Biliary Cholangitis Accepted for Presentation at The Liver Meeting® 2024 October 2024 Read More
COUR Pharmaceuticals Announces Positive Top-line Results from Phase 2a Study of CNP-104 in Primary Biliary Cholangitis September 2024 Read More
COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives August 2024 Read More